Delving into the Latest Updates on Fab I inhibitor(Imagene) with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms-

Target

FabI

Mechanism

FabI inhibitors(enoyl-ACP reductase inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Infectious Diseases

Inactive Indication-

Originator Organization

IMAGENE Co., Ltd.

Active Organization

IMAGENE Co., Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Abstract:Since the early twentieth century, with the isolation of penicillin and streptomycin in the 1940s, the modern era of anti-infective drug development has gained momentum. Due to the enormous success of early drug discovery, many infectious diseases were successfully prevented and eradicated. However, this initial hope was wrongheaded, and pathogens evolved as a significant threat to human health. Drug resistance develops as a result of natural selection’s relentless pressure, necessitating the identification of new drug targets and the creation of chemotherapeutics that bypass existing drug resistance mechanisms. Fatty acid biosynthesis (FAS) is a crucial metabolic mechanism for bacteria during their growth and development. Several crucial enzymes involved in this biosynthetic pathway have been identified as potential targets for new antibacterial agents. In Escherichia coli (E. coli), this pathway has been extensively investigated. The present review focuses on progress in the development of Kas A, Kas B, and Fab H inhibitors as mono-therapeutic antibiotics.

100 Deals associated with Fab I inhibitor(Imagene)

Login to view more data